BENITIONSClinical Trial Intelligence

Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

第4相 完了 NCT04004416

対象疾患Schizophrenia, Bipolar Disorder, Healthy, Psychosis
第4相
スポンサーUniversity of Michigan
ステータス完了
参加者数143 名
介入(薬剤)Placebo and fMRI, Lorazepam and fMRI
開始日2020年1月16日
完了日2025年2月28日
結果公開日2026年6月17日

概要

The purpose of this study is to better understand mental illness and will test the hypotheses that, while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after lorazepam. This study will enroll participants between the ages of 16 and 60, who have a psychotic illness (such as psychosis which includes conditions like schizophrenia, schizoaffective disorder, and mood disorders like bipolar disorder). The study will also enroll eligible participants between the ages of 18 and 60 without any psychiatric illness to compare their brains. The study will require participants to have 3-4 sessions over a few weeks. The initial assessments (may be over two visits) will include a diagnostic interview and several questionnaires (qols) to assess eligibility. Subsequently, there will be two separate functional magnetic resonance imaging (fMRI) sessions in which lorazepam or placebo will be given prior to the fMRI. During the fMRI, the participants will also be asked to answer questions. Additionally, the participants will have their blood drawn, vital signs will be taken, they will be asked to complete more qols, and women of ch

Blood Oxygen Level Dependent (BOLD) Change in Medial Frontal Cortex While Viewing Affective Pictures

Approximately 28 days · AU

Early Psychosis Patients - Lorazepam 0.01 mg/kg-0.174 ± 0.183 AU
Early Psychosis Patients - Lorazepam 0.02 mg/kg-0.037 ± 0.138 AU
Early Psychosis Patients - Placebo-0.177 ± 0.209 AU
Schizophrenia or Schizoaffective Disorder Patients - Lorazepam 0.01 mg/kg-0.167 ± 0.12 AU
Schizophrenia or Schizoaffective Disorder Patients - Lorazepam 0.02 mg/kg-0.046 ± 0.169 AU
Schizophrenia or Schizoaffective Disorder Patients - Placebo-0.175 ± 0.207 AU
p-value0.938
F-Value (Estimation of Variance).136

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。